Tenet Healthcare Corp. (NYSE:THC) stock is currently pricing at roughly $15.67. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 15 analysts covering the company at $24.00. That suggests shares of the stock may have another 35 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $28.00, which would imply another 21 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 3 “Buy” ratings in place. At the same time, 2 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 13 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.
Analysts at Deutsche Bank took a look at THC shares in a research note released on Apr 05, 2017, and issued a Buy rating to this company. Mizuho analysts provided their own take on company recently as well. In a research note published on Feb 24, 2017,the house assigned a Neutral rating to this stock. According to a piece that hit the wires on Nov 22, 2016, researchers at Mizuho reconsidered their prior rating on the stock, and lowered it from Neutral Perform to Underperform.
Tenet Healthcare Corp. (THC) Cap Table Analysis
Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 3.67 percent of the stock.
If we take a more granular look, Mr. Trevor Fetter is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 1,108,162 shares, representing a total current market value of roughly $17364898.54. Mr. Biggs C. Porter is another major player among company insiders, currently holding 466,569 shares as of 0.46%, carrying a current market value of $7311136.23. Dr. Stephen L. Newman, M.D. is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 404,293 shares, valued at around $6335271.31 as of recent close.
We noted a few insider transactions for the stock recently as well.
In a transaction on 2016-11-11, the company’s Director Rittenmeyer Ronald A Purchased 15,000 company shares for 215250. That means, once accounting for this transaction, the Director is left with a stake of 38,783 shares, carrying a current total market value of $607730. In addition, by means of a transaction dated 2016-11-09, Director WILVER PETER M purchased 5,000 shares worth $75950. After that transaction, this investor is left with a total holding of 5,000 shares, representing a total investment value of $78350. We also noted a 2015-11-13 transaction in which THC 10% Owner GLENVIEW CAPITAL MANAGEMENT, L purchased 900,000 shares at a stock price of $32.56, carrying a total value of $29304000, after which, this insider’s investment stands at 17,890,230 shares, with an overall financial value of $280339904.
Tenet Healthcare Corp. (NYSE:THC) Earnings View
In the company’s last quarter, THC EPS moved to $ from $ compared sequentially with the prior quarter. Revenues for the company came in at $M. This stacks up against $M, on a sequential basis.
How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $ per share on $M in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $-0.44 to $0.57. On a year-over-year basis, that compares with an EPS comp of $.